iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
HCV Retreatment Studies
 
 
  EASL: Elbasvir/Grazoprevir Plus Sofosbuvir ± Ribavirin in Treatment-Naive And Treatment-Experienced People With Hepatitis C Virus Genotype 3 Infection and Compensated Cirrhosis: SVR24 Results of the C-ISLE Study - (04/21/17)
 
EASL: MAGELLAN-1, PART 2: GLECAPREVIR/PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE - (04/24/17)
 
DDW/2016: QUARTZ-I: OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND SOFOSBUVIR TREATMENT OF PATIENTS WITH HCV GENOTYPE 1-INFECTION WHO FAILED A PRIOR COURSE OF DAA THERAPY - (05/26/16)
 
EASL: No Impact of RASs on the High Efficacy of SOF/VEL/VOX for 12 Weeks in DAA-Experienced Patients: an Integrated Resistance Analysis of the POLARIS-1 and POLARIS-4 Studies - (04/26/17)
 
EASL: Safety and Efficacy of the Fixed-dose Combination Regimen of Uprifosbuvir (MK-3682) / Grazoprevir / Ruzasvir in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection Who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE) - (04/24/17)
 
EASL: High Sustained Virologic Response Rates at 24 Weeks in Participants With Chronic HCV GT1, 2, or 3 Infection Following 16 Weeks of Grazoprevir/Ruzasvir/Uprifosbuvir (MK-3682) Plus Ribavirin After Having Failed 8 Weeks of a Triple Drug Regimen (Part C of C-CREST-1 & 2) - (04/20/17)

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org